Date: 2015-05-18
Type of information: Nomination
Compound:
Company: Chiasma (USA- MA - Israel)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 18, 2015, Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, announced the appointment of Mark J. Fitzpatrick as the company’s chief financial officer, by June 10, 2015. Mr. Fitzpatrick joins Chiasma from Aegerion Pharmaceuticals where he served as CFO since 2011. He has more than 20 years of financial management experience in both public and private companies. Prior to Aegerion, Mr. Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics, Inc. and vice president and CFO, treasurer and assistant secretary at RenaMed Biologics, Inc. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. Mr. Fitzpatrick previously was a senior auditor with Arthur Andersen & Co. Mr. Fitzpatrick earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.
Financial terms:
Latest news:
